piracetam has been researched along with Acute Post-Traumatic Stress Disorder in 2 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary outcome measure was the PTSD Checklist-Civilian Version (PCL-C)." | 2.72 | Levetiracetam for treatment-refractory posttraumatic stress disorder. ( Kinrys, G; Melo, M; Pardo, TB; Wygant, LE, 2006) |
| "Risperidone and piracetam were found to be effective alone, while their high dose combination, produced potentiating effect in reversing the extinction deficit, behavioral alterations, altered cortical and hippocampal BDNF, IL-6, TNF-α, caspase-3, oxidative stress markers, and neurotransmitter levels." | 1.51 | Co-treatment of piracetam with risperidone rescued extinction deficits in experimental paradigms of post-traumatic stress disorder by restoring the physiological alterations in cortex and hippocampus. ( Akhtar, A; Bansal, Y; Kuhad, A; Sah, SP; Singh, R; Uniyal, A, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uniyal, A | 1 |
| Singh, R | 1 |
| Akhtar, A | 1 |
| Bansal, Y | 1 |
| Kuhad, A | 1 |
| Sah, SP | 1 |
| Kinrys, G | 1 |
| Wygant, LE | 1 |
| Pardo, TB | 1 |
| Melo, M | 1 |
1 trial available for piracetam and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Levetiracetam for treatment-refractory posttraumatic stress disorder.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Diagnostic and Statistical Manual of Mental Disorders | 2006 |
1 other study available for piracetam and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Co-treatment of piracetam with risperidone rescued extinction deficits in experimental paradigms of post-traumatic stress disorder by restoring the physiological alterations in cortex and hippocampus.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Corticosterone; Disease Models, Animal; Drug Synerg | 2019 |